Drug
Edp 938 Dose 1
Edp 938 Dose 1: highest development phase Phase 2, developed by Enanta Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-938 Dose 1 NCT03691623 | Phase 2 | RSV Infection |
Latest
No recent events.
Follow Edp 938 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.